Bisphosphonates--mechanisms of action in multiple myeloma.
Bisphosphonates--mechanisms of action in multiple myeloma.
复制标题
双膦酸盐——多发性骨髓瘤的作用机制。
作者：
C. Shipman;Michael J. Rogers;Karin Vanderkerken;B. Camp;R. Graham;G. Russell;P. Croucher
双膦酸盐是一类抗骨吸收药物，可有效治疗破骨细胞介导的骨病，包括溶骨性骨病。这是多发性骨髓瘤患者的一个主要临床特征。最近，在一些多发性骨髓瘤患者中观察到帕米膦酸盐治疗后生存率的增加，这提高了双膦酸盐也可能具有抗肿瘤作用的可能性。我们已经证明了双膦酸盐可以在体外对人类骨髓瘤细胞具有抗肿瘤作用，并且这些抗肿瘤作用是由强效含氮双膦酸盐诱导的，是抑制甲羟戊酸途径酶的结果。然而，我们和其他人无法通过多发性骨髓瘤小鼠模型在体内证明强效二膦酸盐依班膦酸盐的抗肿瘤作用。因此，只有通过研究接受双膦酸盐治疗的患者，我们才能确定这些化合物是否具有重要的临床抗肿瘤作用。
Bisphosphonates are a class of anti-resorptive drugs, which are effective in the treatment of osteoclast-mediated bone disease, including the osteolytic bone disease. which is a major clinical feature of patients with multiple myeloma. Recently, increases in survival following treatment with pamidronate have been observed in some patients with multiple myeloma, raising the possibility that bisphosphonates may also have an anti-tumour effect. We have demonstrated that bisphosphonates can have an anti-tumour effect in human myeloma cell in vitro, and that these anti-tumour effects induced by potent nitrogen-containing bisphosphonates are a result of inhibition of enzymes of the mevalonate pathway. However, we and others have been unable to demonstrate an anti-tumour effect of the potent bisphosphonate ibandronate in vivo, using murine models of multiple myeloma. It is therefore likely that only by studying patients receiving bisphosphonates will we be able to determine whether these compounds have a clinically important anti-tumour effect.
影响因子：
20.3
作者：
Dallas, SL;Garrett, IR;Mundy, GR
通讯作者：
Mundy, GR